启动肝脏内细胞通路以加速纳米颗粒的肝胆清除
Yunfeng Ren1, Fang Mei1, Huixu Lu1
1School of Biomedical Sciences and Engineering, South China University of Technology, Guangzhou International Campus, Guangzhou 511442, P.R. China.
ACS nano
|February 21, 2026
概括
启动肝脏以抑制克拉特林介导内细胞分裂 (CME) 加快了纳米颗粒的消除. 这一策略增强了肝细胞的外细胞形成,减少了纳米颗粒的积累,并改善了纳米药物输送.
科学领域:
- 纳米技术 纳米技术
- 肝胆科学 肝胆科学
- 药物运输 药物运输 药物运输
背景情况:
- 长时间的纳米药物的肝脏积累阻碍了临床使用,特别是对于不可生物降解的纳米颗粒.
- 目前的战略重点是减少肝脏吸收,很少有人解决吸收后加速排泄问题.
研究的目的:
- 开发一种广泛适用的战略,以加快纳米颗粒的肝胆排泄.
- 调查肝脏内细胞通路在纳米粒子清除中的作用.
主要方法:
- 在小鼠中使用 хлорпромазин 抑制克拉斯林介导的内细胞衰竭 (CME).
- 从肝细胞和巨细胞中评估纳米粒子细胞内贩运和外细胞形成.
- 评估各种纳米颗粒的肝胆清除和肝脏保留.
- 在小鼠瘤模型中进行测试,以评估纳米药物输送效率.
主要成果:
- 抑制CME显著增强了来自肝细胞和巨细胞的纳米颗粒外细胞.
- 改变的细胞内流通将纳米颗粒转移到戈尔吉,以加快细胞外的速度.
- 普罗马зин初始化加速了肝胆清除,并减少了各种纳米颗粒的肝脏保留.
- 肝性CME抑制加速了消除,而不会影响瘤向疗效.
结论:
- 通过CME抑制来启动肝脏内细胞路径是加速纳米颗粒消除的多功能策略.
- 这种方法为减少纳米药物的肝脏积累提供了对现有方法的补充策略.
相关概念视频
Hepatic Drug Clearance: Role of Transporters
335
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
335
Drug Elimination: Non-Renal Routes
3.4K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
3.4K
Hepatic Drug Excretion: Enterohepatic Cycling
3.0K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
3.0K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
337
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
337
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
272
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
272
Bioavailability Enhancement: Drug Permeability Enhancement
248
Body:After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt...
248


